Evidence map›Paper›PMID 39773263›Full record

ArticleMolecular neurodegeneration2025

VCP regulates early tau seed amplification via specific cofactors.

Sushobhna Batra, Jaime Vaquer-Alicea, Clarissa Valdez, Skyler P Taylor, Victor A Manon, Anthony R Vega, Omar M Kashmer, Sourav Kolay, Andrew Lemoff, Nigel J Cairns and 2 more

Abstract read
In one paragraph

Article in Molecular neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Astrocyte-Predominant Tau Pathology in a Patient With VCP R191Q Variant.Neuropathology : official journal of the Japanese Society of Neuropathology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Progress toward a comprehensive brain protein interactome.Biochemical Society transactions · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Sushobhna BatraCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, 6124 Harry Hines Blvd, Dallas, TX, NS8.334, United States.ORCID 0000-0002-0964-975X
Jaime Vaquer-AliceaCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, 6124 Harry Hines Blvd, Dallas, TX, NS8.334, United States.
Clarissa ValdezCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, 6124 Harry Hines Blvd, Dallas, TX, NS8.334, United States.
Skyler P TaylorCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, 6124 Harry Hines Blvd, Dallas, TX, NS8.334, United States.
Victor A ManonCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, 6124 Harry Hines Blvd, Dallas, TX, NS8.334, United States.
Anthony R VegaCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, 6124 Harry Hines Blvd, Dallas, TX, NS8.334, United States.
Omar M KashmerCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, 6124 Harry Hines Blvd, Dallas, TX, NS8.334, United States.
Sourav KolayCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, 6124 Harry Hines Blvd, Dallas, TX, NS8.334, United States.
Andrew LemoffDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Nigel J CairnsDepartment of Clinical and Biological Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Charles L WhiteDepartment of Pathology, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Marc I DiamondCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, 6124 Harry Hines Blvd, Dallas, TX, NS8.334, United States. marc.diamond@utsouthwestern.edu.

Funding

Mechanism of cell uptake for pathogenic tau seedsR01AG071502 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI MARC I DIAMOND · 2022 to 2026
$3.4M
Mechanism of modulation of huntingtin exon 1 aggregation by profilinR01NS089932 · NINDS · WASHINGTON UNIVERSITY · PI DIAMOND, MARC I, LANGEN, RALF · 2016 to 2020
$2.8M
Department of Defense Grant W81XWH-13-2-017NIA NIH HHS R01 AG071502NIH HHS 1R21AG064418-01A1NIH HHS 1RF1AG059689-01A1NINDS NIH HHS R01 NS089932
6 · The paper itself

Abstract

backgroundNeurodegenerative tauopathies may progress based on seeding by pathological tau assemblies, whereby an aggregate is released from one cell, gains entry to an adjacent or connected cell, and serves as a specific template for its own replication in the cytoplasm. Seeding into the complex cytoplasmic milieu happens within hours, implying the existence of unknown factors that regulate this process.

methodsWe used proximity labeling to identify proteins that control seed amplification within 5 h of seed exposure. We fused split-APEX2 to the C-terminus of tau repeat domain (RD) to reconstitute peroxidase activity 5 h after seeded intracellular tau aggregation. Valosin containing protein (VCP/p97) was the top hit. VCP harbors dominant mutations that underlie two neurodegenerative diseases, multisystem proteinopathy and vacuolar tauopathy, but its mechanistic role is unclear. We used immortalized cells and human neurons to study the effects of VCP on tau seeding. We exposed cells to fibrils or brain homogenates in cell culture media and measured effects on uptake and induction of intracellular tau aggregation following various genetic and pharmacological manipulations of VCP.

resultsVCP knockdown reduced tau seeding. Chemical inhibitors had opposing effects on seeding in HEK293T tau biosensor cells and human neurons: ML-240 increased seeding efficiency, whereas NMS-873 decreased it. The inhibitors only functioned when administered within 8 h of seed exposure, indicating a role for VCP early in seed processing. We screened 30 VCP co-factors in HEK293T biosensor cells by genetic knockout or knockdown. Reduction of ATXN3, NSFL1C, UBE4B, NGLY1, and OTUB1 decreased tau seeding, as did NPLOC4, which also uniquely increased soluble tau levels. By contrast, reduction of FAF2 increased tau seeding.

conclusionsDivergent effects on tau seeding of chemical inhibitors and cofactor reduction indicate that VCP regulates this process. This is consistent with a cytoplasmic processing complex centered on VCP that directs seeds acutely towards degradation vs. amplification.

Indexed as

tau ProteinsValosin Containing ProteinAdenosine TriphosphatasesCell Cycle ProteinsHumansNeuronsTauopathiesAdenosine TriphosphatasesCell Cycle Proteinstau ProteinsValosin Containing ProteinVCP protein, humanAPEX2CofactorsDisaggregasep97SeedingTauVCP

Identifiers

PMID39773263
PMCPMC11707990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.